How Biotech Freed Itself From FDA Shackles: Trevena’s 108.72% Stock Rise

This article was written by Graham Ellinson, a Financial Analyst at I Know First currently studying Mathematics at Northumbria University Newcastle.  

 Source: logosandbrands.directory

Highlights

      • OLINVO and other pipeline products drive TRVN growth
      • The rate of FDA drug approval has risen significantly across the board over the last year
      • I Know First algorithm is currently bullish on TRVN
      • premiumRead The Full Premium Article

        Subscribe to receive exclusive PREMIUM content Here

Winning Stock Forecast: ENDP Returns up to 30.67% in 1 Month with global expansion and counter lawsuits

“One of the biggest challenges to medicine is the incorporation of information technology in our practices.”

– Samuel Wilson

(Source: Air Force Medical Service)

Endo International plc, incorporated on October 31, 2013, is a generics and specialty branded pharmaceutical company. The company has three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has its own brand names and its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics

Read More

DVAX Stock Forecast: Table Is Being Set – Revenue Growth Is On The Way

  The article was written by Amber Zhou, a Financial Analyst at I Know First.

DVAX Stock Forecast

“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.

(Source: mmm-online.com)

 

Highlights:

  • Competitive Edge and Huge Market Potential from Heplisav-B®
  • Market Doubts about Trial Data of Immuno-Oncology Platform
  • Strong Cash Position from Debt Financing
  • Current I Know First Bullish Forecast For DVAX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Winning KERX Stock Forecast: Keryx Biopharmaceuticals Continues To Save Its Patients And Surges With 19.55% In 7 Days

“Revenue growth in the first quarter of 2018, as compared to the first quarter of 2017, was driven by an increase in Auryxia prescription and tablet demand, partially offset, by a reduction in the net price realized per tablet due to an increase in our gross-to-net adjustment”

– Scott Holmes, Senior Vice President and CFO of Keryx Biopharmaceuticals

[Image Source: Glassdoor]

Over the 7 days period from May 9th to May 16th, 2018 KERX stock price saw significant price jump of more than 19%. The overall KERX stock performance indicators for the last quarter suggest that this may be

Read More

ImmunoGen Stock: Expected Growth in a Volatile Industry

    The article was written by Harry Chiang, a Financial Analyst at I Know First.

ImmunoGen Stock Analysis

"Almost everybody is enthusiastic about the promise of biotechnology to cure disease and to relieve suffering" - Leon Kass, American Scientist
Summary:
  • The Birth of ImmunoGen
  • Keeping Cash Close At Hand
  • An Impressive Lead Compound
  • Major Partnerships
  • An Enthusiastic Outlook on the Future

cisco stock priceRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

I Know First Review Weekly Algorithmic Performance: July 23, 2017

I Know First Review

On July 23, 2017, our weekly newsletter was sent out to all I Know First subscribers, which can be found here. Below, you may find the I Know First Review, highlighting the algorithm’s performance for this past week. I Know First Review

Amicus Stock Quick Win By The Algorithm: FOLD Climbs On FDA Decision

Quick Win By The Algorithm

Read The Full Forecast

             Amicus Stock
Pages:123456»